In support, NMA, as well as MDS studies, revealed that complex has greater stability and flexibility (Figure 5), which in conclusion recommends andrographolide possesses therapeutic potentiality in blocking TLR4-MD2-mediated inflammatory pathophysiological consequences of COVID-19 patients. The gene discussed is TLR4; the disease is COVID-19.